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Abstract
Background: In Korea, where gastric cancer is highly prevalent, biennial endoscopy is recommended among
individuals over 40. Even under regular screening, some are still diagnosed at advanced stages. We aimed to
identify characteristics of interval gastric neoplasms (IGNs) with rapid progression.
Results: Newly-diagnosed gastric neoplasms detected in screening endoscopy between January 2004 and May
2016 were reviewed. Among them, those who had previous endoscopy within 2 years were enrolled. Endoscopic
findings, family history of gastric cancer, smoking, and H. pylori status were analysed. Totally, 297 IGN cases were
enrolled. Among them, 246 were endoscopically treatable IGN (ET-IGN) and 51 were endoscopically untreatable
IGNs (EUT-IGN) by the expanded criteria for endoscopic submucosal dissection. Among EUT-IGNs, 78% were
undifferentiated cancers (40/51) and 33% showed submucosal invasion (13/40). They were median 2.0 cm in size
and more commonly located in the proximal stomach than ET-IGNs (70.6% vs. 41.9%, p < 0.001). EUT-IGN was
independently related with age < 60 (OR, 2.09; 95%CI, 1.03–4.26, p = 0.042), H. pylori (OR, 2.81; 95%CI, 1.20–6.63, p =
0.018), and absent/mild gastric atrophy (OR, 2.67; 95%CI, 1.25–5.72, p = 0.011). Overall and disease-specific survival
were not significantly different between the two groups, however EUT-IGN tended to have short disease-specific
survival (overall survival, p = 0.143; disease-specific survival, p = 0.083).
Conclusions: Uniform screening endoscopy with two-year interval seems not enough for rapid-growing gastric
neoplasms, such as undifferentiated cancers. They tended to develop in adults younger than 60 with H. pylori
infection without severe gastric atrophy. More meticulous screening, especially for proximal lesions is warranted for
adults younger than 60 with H. pylori infection before development of gastric atrophy.
Keywords: Gastric neoplasm, Screening endoscopy, H. pylori, Atrophic gastritis, Undifferentiated histology
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: philomed@hanmail.net; medjsj7@hanmail.net
†Ji Hyun Song and Su Jin Chung contributed equally to this work.
1Department of Internal Medicine, Healthcare Research Institute, Healthcare
System Gangnam Center, Seoul National University Hospital, 152, Teheran-ro,
Gangnam-gu, Seoul 06236, South Korea
Full list of author information is available at the end of the article
Lim et al. BMC Cancer          (2021) 21:218 
https://doi.org/10.1186/s12885-021-07929-y
Background
Although its incidence and mortality are continuously
decreasing, gastric cancer is still the 5th most common
cancer and the 3rd leading cause of cancer-related death
worldwide. Annually, more than a million new gastric
cancer cases arise and more than 780,000 gastric cancer-
related deaths occur over the world [1]. Especially in
East Asia, gastric cancer is one of the greatest concerns
due to the extremely high incidence [2–4]. In Korea, al-
though the incidence of Helicobacter pylori (H. pylori)
infection, which is one of the greatest risk factors for
gastric cancer, has been gradually decreased, showing
66.9% in 1998, 59.6% in 2005, 54.4% in 2011, and 43.9%
in 2016 [5], gastric cancer is still the most common can-
cer and its age-standardised rate reached up to 33.3 in
2017 statistics [6]. The National Cancer Screening Pro-
gram in Korea, which covers biennial upper gastrointes-
tinal endoscopy for those over 40 years old, has been in
place since 2004 [7, 8]. Since then, the five-year survival
rate of gastric cancer in Korea has considerably in-
creased, which although is still an unsatisfactory rate at
less than 80% [9]. This can be attributed in part to insuf-
ficient endoscopic screening rate of only about 60% [10].
However, even despite regular screening, some are still
diagnosed with advanced diseases.
Interval cancer is defined as cancer detected between
regular screenings, which can be a great setback to the
cancer screening. The concept of “interval cancer” is
well established in colorectal cancer, as a quality indica-
tor of screening [11]. However, little has been investi-
gated about interval gastric cancer. This terminology of
“interval gastric cancer” is occasionally used only in Far
East where nationwide endoscopic screening for gastric
cancer is established [12]. Interval cancer can be missed
lesion or true new lesion. Qualified endoscopy may re-
duce missing rate, however, new lesions with rapid pro-
gression are inevitable. Also, whether the two-year
interval of gastric cancer screening is optimal is still on
debate. Several studies have reported better outcome of
endoscopic screening with less than 2 years of interval
[13–15]. In current study, we defined “interval gastric
neoplasm (IGN)” as gastric neoplasm including dysplasia
and cancer detected within 2 years after negative screen-
ing. We assumed that better understanding on IGN will
enable better tailored-screening for gastric cancer. This
study aimed to identify characteristics of IGN detected




We retrospectively reviewed medical records of patients
who were newly diagnosed with gastric neoplasms, in-
cluding dysplasia and cancer, during screening
endoscopy at a single health-checkup center between
January 2004 and May 2016. Among them, those who
underwent previous endoscopy within 2 years were en-
rolled. Endoscopy was performed with Fujinon VP-XL
402/4400 until 2009 and Olympus CV-260SL/290 there-
after. In order to identify potential risk factors for rapid
progression, we reviewed the following data: endoscopic
findings, family history of gastric cancer within 1st de-
gree relatives, smoking history (never vs. former/
current), and H. pylori infection status. Those with ei-
ther anti-H. pylori IgG antibody sero-positivity, positive
result in rapid urease test, or histologic findings of H.
pylori in Giemsa staining were considered to have H.
pylori infection. Anti-H. pylori antibody was tested with
enzyme-linked immunosorbent assay (H. pylori-EIA-
Well, Radim, Rome, Italy) until March 2013 and with
chemiluminescent microparticle immunoassay (Immulite
2000 CMIA, Siemens, UK) since April 2013. Anti-H. pyl-
ori IgG levels higher than 30 U/mL by EIA and 1.10 IU/
mL by CIMA were regarded positive. We also reviewed
the previous endoscopic images to check if any abnor-
mality had been found at the same location where the
neoplasm developed. The Institutional Review Board of
our center, which complies with the declaration of
Helsinki, approved this study (IRB No. H-1504-045-663).
Patient consent was waived because of the retrospective
nature of this study.
Definitions
In this study, endoscopically treatable-IGN (ET-IGN)
was defined as adenoma or gastric cancer detected
within 2 years after negative screening endoscopy, which
is within the expanded criteria for endoscopic submuco-
sal dissection (ESD), except for undifferentiated hist-
ology [16]. This includes low- to high-grade dysplasia
regardless of size of the lesion or well- to moderately-
differentiated adenocarcinoma. As for adenocarcinoma,
following three size criteria were included: mucosal can-
cer without ulceration regardless of size, mucosal cancer
< 3 cm with ulceration, or submucosal cancer < 3 cm
with SM1 invasion.
Endoscopically untreatable-IGN (EUT-IGN) was de-
fined as gastric cancer detected within 2 years after
negative screening endoscopy, which is over the ex-
panded criteria for ESD, including undifferentiated hist-
ology regardless of size.
Severity of gastric atrophy was defined using the
Kimura-Takemoto classification designed for the cat-
egorisation of endoscopic atrophic gastritis [17] by three
expert endoscopists (JHL, JHS, SJC) under mutual dis-
cussion. Intestinal metaplasia was defined as gross endo-
scopic finding with ash-colored mucosal nodularity.
Biopsy specimens were examined and reported accord-
ing to the WHO criteria [18]. As for gastric cancer, well-
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to-moderately differentiated tubular adenocarcinoma or
papillary adenocarcinoma was classified as differentiated
type, while poorly differentiated adenocarcinoma, signet-
ring cell carcinoma (poorly cohesive carcinoma), or mu-
cinous carcinoma was classified as undifferentiated type.
Statistical analysis
For categorical variables, Chi-square test or Fisher’s
exact test was applied, while Student t-test was used to
compare continuous variables. Multivariable analysis was
performed by using logistic regression analysis with po-
tential risk factors found in univariable analyses with
clinical relevance. Survival analysis was performed with
log-rank test and Cox proportional hazard model. All
the analyses were performed with the Statistical Package
for the Social Sciences, version 23.0 for Windows (SPSS,
Seoul, Korea). All tests were two-sided and p values <
0.05 were considered statistically significant.
Results
Baseline clinical characteristics
Overall, 625 patients who were newly diagnosed with
gastric neoplasms were reviewed (Fig. 1). Among them,
300 patients who underwent previous upper gastrointes-
tinal endoscopy within 24months were included. One
patient who had previous gastrectomy for peptic ulcer
and two patients with unclear final pathology were ex-
cluded, and the remaining 297 individuals were finally
enrolled. Among the total 297 lesions in 297 individuals,
149 were diagnosed with low-grade dysplasia, 22 with
high-grade dysplasia, 124 with early gastric cancer
(EGC), and 2 with advanced gastric cancer (AGC).
Altogether, 246 cases were ET-IGNs and 51 cases were
EUT-IGNs. There has been no one with synchronous le-
sions in this study.
Overall mean age was 59.4 and the EUT-IGN group
was younger than the ET-IGN group (55.0 ± 8.5 vs
60.3 ± 9.0, p < 0.001, Table 1). Between the two groups,
the EUT-IGN group had less proportion of males (58.8%
vs 79.7%, p = 0.001) and smaller body mass index (BMI)
at diagnosis than the ET-IGN group. Past history of can-
cer other than gastric cancer was not significantly differ-
ent between the two groups. Overall family history of
gastric cancer was found in 22.6% and it was not differ-
ent between the two groups. Overall H. pylori infection
rate was 71.6% and which was higher in EUT-IGN
group, although without statistical significance (82.4%
vs. 69.4%, p = 0.062). Smoking rate was significantly
higher in the ET-IGN group (69.5% vs 49.0%, p = 0.005).
The H. pylori infection rate among IGNs were higher
than that among the general Korean population (59.6%
in 2005; 54.4% in 2011; 43.9% in 2016) [5]. However,
despite the decreasing general trend of H. pylori infec-
tion rate, the rate among IGN rather somewhat in-
creased although without statistical significance (69.6%
in 2004–2008; 68.2% in 2009–2013; 78.3% in 2014–
2016; p = 0.231). Among the total 297 patients, about
10% (n = 31) had abnormal lesion at the same location in
the previous endoscopy, however, the biopsies all re-
vealed negative result for neoplasm, only with the find-
ing of active gastritis. However, the rate of previous
abnormal lesion at the same location was not different
between the two groups (13.7 and 9.8% in the EUT-IGN
and the ET-IGN groups, respectively, p = 0.399). Atro-
phic gastritis and intestinal metaplasia were significantly
more common in the ET-IGN group than in the EUT-
Fig. 1 Study flow chart showing patient enrollment
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IGN group. Also, moderate to severe atrophic gastritis
was more frequent in the ET-IGN group (81.7% vs
49.1%, p = 0.002).
Pathological characteristics of interval neoplasms
Table 2 shows the pathological characteristics of 297
IGNs. Overall median size was less than 1.0 cm, while
the median size of EUT-IGNs was as large as 2.0 cm. Ul-
ceration was ten times more commonly found in the
EUT-IGN group than in the ET-IGN group (31.4% vs
3.3%, p < 0.001). Undifferentiated histology accounted
for 80% of the EUT-IGNs, and submucosal invasion was
detected in about one-third of the EUT-IGNs (13/40,
32.5%). ET-IGNs were most commonly found in the
lower third of the stomach and then in the middle and
upper third, whereas EUT-IGNs were commonly found
in the order of the upper, middle, and lower third.
In this study, there were two cases of AGC (Table 3).
Both were female nonsmokers with undifferentiated hist-
ology and both lesions were located in the upper third of








Age, mean ± SD (yr) 59.4 ± 9.1 60.3 ± 9.0 55.0 ± 8.5 < 0.001
Male sex (%) 226 (76.1) 196 (79.7) 30 (58.8) 0.001
BMI, median (IQR) (kg/m2) 24.4 (22.4–26.0) 24.6 (22.6–26.0) 23.5 (21.3–25.8) 0.030
Previous diagnosis with other cancer (%) 37 (12.5) 31 (12.5) 6 (11.8) 0.869
Family history of gastric cancer (%) 67 (22.6) 53 (21.5) 14 (27.5) 0.358
H. pylori infection‡ (%) 212/296 (71.6) 170/245 (69.4) 42/51 (82.4) 0.062
Current or ex-smoker (%) 196 (66.0) 171 (69.5) 25 (49.0) 0.005
Previous abnormality at the same location (%) 31 (10.4) 24 (9.8) 7 (13.7) 0.399
Gastric atrophy, Kimura-Takemoto classification (%) 0.002
Absent (C0) 12 (4.0) 7 (2.8) 5 (9.8)
Mild (C1, C2) 54 (18.2) 38 (15.4) 16 (31.4)
Moderate (C3, O1) 165 (55.6) 141 (57.3) 24 (47.1)
Severe (O2, O3) 66 (22.2) 60 (24.4) 6 (11.8)
Intestinal metaplasia§ (%) 175 (58.9) 156 (63.4) 19 (37.3) 0.001
Interval since last upper GI endoscopy, median (IQR) (months) 12.0 (11.0–15.0) 12.0 (11.0–15.0) 12.0 (11.0–14.0) 0.847
ET-IGN endoscopically treatable gastric neoplasm; EUT-IGN endoscopically untreatable gastric neoplasm; SD standard deviation; BMI body mass index; IQR
interquartile range; H. pylori, Helicobacter pylori; GI gastrointestinal
† Comparison between ET-IGN and EUT-IGN
‡ Some denominators do not match the total numbers because of missing data
§ Endoscopically diagnosed intestinal metaplasia
Continuous variables are presented as the mean ± standard deviation or median with interquartile range according to fitness of normal distribution and
categorical variables are presented as numbers and effective percentage excluding missing data








Size, median (IQR) (cm) 0.90 (0.60–1.60) 0.80 (0.50–1.20) 2.00 (1.40–3.00) < 0.001
Ulcer (%) 24 (8.1) 8 (3.3) 16 (31.4) < 0.001
Undifferentiated histology (%) 40 (13.5) 0 (0.0) 40 (78.4) –
Submucosal invasion‡ (%) 14/282 (5.0) 1/242 (0.4) 13/40 (32.5) < 0.001
Location (%) < 0.001
Upper third 58 (19.5) 39 (15.9) 19 (37.3)
Middle third 81 (27.3) 64 (26.0) 17 (33.3)
Lower third 158 (53.2) 143 (58.1) 15 (29.4)
ET-IGN endoscopically treatable gastric neoplasm; EUT-IGN, endoscopically untreatable gastric neoplasm; IQR interquartile range
† Comparison between ET-IGN and EUT-IGN
‡ Some denominators do not match the total numbers because of missing data
Continuous variables are presented as the median with interquartile and categorical variables are presented as numbers and effective percentage excluding
missing data
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the stomach. One had a 15.5 cm-sized lesion, with linitis
plastica. In retrospective review, similar fold thickening
was found at the same location of the previous endo-
scopic images, which was found to be overlooked at that
time after a negative result using forceps-biopsy. The
other case was detected with only 1.5 cm-sized ulcero-
fungating lesion with non-specific findings from the pre-
vious endoscopy. Diffuse peritoneal seeding was found
at the time of staging workup and this patient died after
14.8 months later.
Multivariable analysis for risk of EUT-IGN
We performed multivariable analysis to evaluate the risk
for EUT-IGN with potentially associated variables which
showed p values < 0.10 in the univariable analyses
(Fig. 2). In this analysis, age < 60 [odds ratio (OR), 2.09;
95% CI, 1.03–4.26; p = 0.042], H. pylori infection (OR,
2.81; 95% CI, 1.20–6.63; p = 0.018), and absent/mild at-
rophy (OR, 2.67; 95% CI, 1.25–5.71; p = 0.011) showed
independent association with EUT-IGN under adjust-
ment. Meanwhile, female sex (OR, 1.56; 95% CI, 0.56–
4.33; p = 0.397), BMI (OR, 0.94; 95% CI, 0.84–1.05; p =
0.272), and smoking (OR, 0.66; 95% CI, 0.25–1.72; p =
0.398) were not independently related with EUT-IGN.
Survival analysis of the IGNs
During the median follow-up duration of 58.4 months
(interquartile range, 30.3–94.5), eight cases of death oc-
curred in the ET-IGN group and four in the EUT-IGN
group. Among them, two in each group were gastric
cancer-related deaths. The detailed profiles of the two
gastric cancer-related deaths developed among ET-IGN
group are described in Table 4. Overall survival showed
a tendency of lower survival in the EUT-IGN group than
ET-IGN group, however, this failed to show statistical
significance (p = 0.143, Fig. 3a). Under Cox proportional
hazard model, EUT-IGN showed HR of 2.34 with 95%
CI between 0.72 and 7.94, compared with ET-IGN.
Meanwhile, gastric cancer-specific survival also showed
a tendency of lower rate in EUT-IGN than in ET-IGN,
with relatively near significance (p = 0.083, Fig. 3b).
Under Cox proportional hazard model, EUT-IGN
showed HR of 4.804 with 95% CI between 0.68 and
34.14.
Subgroup analysis among interval gastric cancers (IGCs)
We also performed subgroup analysis among IGCs ex-
cluding gastric dysplasia. Among them, endoscopically
untreatable–IGCs (EUT-IGCs) were younger with larger
composition of females, and less likely smokers (Supple-
mentary Table 1). Also EUT-IGCs were less likely to
have moderate-to-severe atrophy or intestinal metaplasia
compared with endoscopically treatable-IGCs (ET-
IGCs). Obviously, EUT-IGCs were more likely to have
ulcers and larger lesions with submucosal invasion.
In multivariable analysis, age (OR, 0.94; 95% CI, 0.89–
0.99; p = 0.01), female gender (OR, 4.00; 95% CI, 1.43–
11.14; p = 0.01), and absent/mild atrophy (OR, 2.96; 95%
CI, 1.08–8.07; p = 0.03) were shown to be independently
associated with EUT-IGC. Although without statistical
significance, those with abnormalities found at the same
location in the previous exam were shown to have high
tendency to develop EUT-IGC (OR, 4.29; 95% CI, 0.86–
21.26; p = 0.08).
In terms of survival, EUT-IGCs were more likely to
have poorer overall survival and gastric cancer-specific
survival, although without statistical significance (Sup-
plementary Fig. 1A and 1B).
Subgroup analysis among IGNs detected since 2010
As the scope used in the screening has been improved
over time, the endoscopic images taken before 2010
were of poor quality with low resolution compared with
those taken thereafter with new Olympus scope. There-
fore, we performed subgroup analysis among IGNs de-
tected since 2010. Since 2010, 204 IGNs were detected
Fig. 2 Odds ratios and 95% confidence intervals of potential risk factors for endoscopically untreatable-gastric neoplasm. BMI, body mass index;
H. pylori, Helicobacter pylori
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including 170 ET-IGN and 34 EUT-IGN. Their baseline
and pathologic characteristics were not much different
from those of overall subjects (Supplementary Table 2).
In multivariable analysis, age < 60 (OR, 0.94; 95% CI,
0.90–0.99; p = 0.02), H. pylori infection (OR, 3.92; 95%
CI, 1.23–12.46; p = 0.02), and absent/mild atrophy (OR,
3.30; 95% CI, 1.25–8.72; p = 0.02) were revealed as inde-
pendent risk factors for EUT-IGN, just like in the overall
subjects.
Discussion
Overall, among the 297 patients with IGNs diagnosed by
screening endoscopy, 17% had EUT-IGN and most of
them were undifferentiated adenocarcinoma. After mul-
tivariable analysis, age < 60, H. pylori infection, and ab-
sent/mild atrophic gastritis were shown to be associated
with EUT-IGN among health screening population.
Also, patients with EUT-IGN showed a tendency of
lower gastric cancer-specific survival compared with
those with ET-IGN.
In this study, IGN was defined as gastric dysplasia
or cancer diagnosed between biennial endoscopic
screenings. As the concept of interval cancer is not
widely used for gastric cancer, there have been little
references regarding this. Several previous studies
dealt with interval gastric cancer [19, 20], however
our study is somewhat different from those studies.
Usually, the concept interval cancer is used for qual-
ity indicator of screening. This means that it is highly
probable that interval cancer is a missed lesion in the
previous screening. However, interval cancer might be
a newly developed lesion after a negative screening,
as well. Unlike previous studies, we focused on the
latter possibility, as we all reviewed previous endo-
scopic images and confirmed no abnormal findings.
Also, considering the highly improved 5-year survival
rate of gastric cancer, we need to more focus on the
quality of life rather than mortality now-a-days.
Whether to treat with surgery or endoscopic resection
is one of the great component deciding the quality of
life. Therefore, we also included dysplasia to further
investigate the adequacy of 2 year interval and risk
for rapid progression which disables endoscopic resec-
tion. In this concept the new definition of “IGN” was
made.
It is well known that gastric cancer prognosis highly
depends on the stage at diagnosis [21]. Also, it is widely
accepted that EGC which is defined as gastric cancer
confined to mucosa has very low rate of lymph node in-
vasion [22] and is related with excellent 5-year survival
rate compared with AGC [23]. Therefore gastric cancer
is often divided into EGC and AGC considering its dif-
ferent treatment modality and prognosis. Also, gastric
dysplasia has been widely accepted as precancerous le-
sion, since Correa et al. hypothesised the gastric carcino-
genesis cascade which includes the serial progression of
chronic inflammation into atrophic gastritis, intestinal
metaplasia, gastric dysplasia, and finally gastric adeno-
carcinoma [24]. Therefore, we further divided IGN into
ET-IGN and EUT-IGN according to the expanded cri-
teria for ESD. Since ESD was first introduced in the
1990s, it has largely replaced the role of radical gastrec-
tomy for EGC without lymph node metastasis. These
days, ESD is established as one of the standard treatment
modalities for early gastric neoplasm because it enables
en bloc resection with less invasiveness than conven-
tional surgery [25–27]. The quality of life in gastric can-
cer patients largely depends on whether endoscopic
treatment is possible or not. With the prevalence of
endoscopic screening, the proportion of early-stage diag-
nosis of gastric neoplasm increases, and thus the role of
endoscopic treatment such as ESD is continuously grow-
ing as well. With the development of diagnostic and
therapeutic technology, the EGC diagnosis rate now-
adays reaches up to 80% in countries with high inci-
dence rates of gastric cancer like Korea and Japan [14,
Fig. 3 Kaplan-Meier curves comparing ET-IGN and EUT-IGN: (a) Overall survival; (b) Gastric cancer-specific survival. ET-IGN, endoscopically
treatable-gastric neoplasm; EUT-IGN, endoscopically untreatable-gastric neoplasm
Lim et al. BMC Cancer          (2021) 21:218 Page 8 of 11
28]. Thus we further sub-classified gastric neoplasms ac-
cording to the criteria for ESD to better reflect the prog-
nosis and quality of life in patients with IGNs.
In this study, the clinicopathological characteristics
of IGNs were not different from those of general gas-
tric cancers in terms of mean age, male predomin-
ance, and the rate of H. pylori infection [1].
Meanwhile, patients with EUT-IGNs showed a signifi-
cant difference; they were younger, with relatively
higher proportion of female, with lower smoking rate.
They had lower grade of atrophic gastritis and less
likely to have intestinal metaplasia, despite higher rate
of H. pylori infection and which are similar with the
characteristics seen in diffuse type gastric cancer. Dif-
fuse type gastric cancer is also related with younger
age, rapid progression [29], and higher rate of H. pyl-
ori infection [30]. On the other hand, intestinal type
GC is known to be more associated with multi-step
carcinogenic cascade of chronic inflammation which
comprises atrophic gastritis, intestinal metaplasia, and
dysplasia [24, 31, 32]. In our study, among the EUT-
IGNs, 80% were undifferentiated gastric cancers with
Lauren diffuse type. As for the tumor location, EUT-
IGNs showed tendency to be located at the upper or
middle third of the stomach, while ET-IGNs were
most commonly found at the lower third. This was
also in line with the results of previous research
which compared diffuse and intestinal type EGCs
[30]. The relationship between H. pylori infection and
the upper third gastric cancer has been controversial.
However, a previous meta-analysis on this issue has
shown that the relationship between cardia cancer
and H. pylori infection is highly positive in Eastern
countries where gastric cancer incidence is high, while
it tends to be neutral or even negative in Western
countries with low gastric cancer prevalence [33].
This phenomenon might be attributed to the co-
existence of two distinct types of cancers, one similar
to H. pylori-related gastric cancer and the other simi-
lar to acid/bile-related esophageal cancer, which are
prevalent in Eastern and Western countries, respect-
ively. Since the upper part of the stomach is usually
observed less thoroughly than the antrum, there
might have been missed lesions during the previous
endoscopic examination. However, on the review of
the previous endoscopic images, any abnormalities at
the same location were all confirmed to be free of
neoplastic change. Only one case with diffuse fold
thickening in the previous exam, which showed nega-
tive result from the forcep biopsy was finally diag-
nosed as AGC with linitis plastica by using CT scan
after the next screening endoscopy. This case gives a
lesson that conscious evaluation is needed for cases
suspicious for Bormann type IV AGCs. The two cases
of interval AGCs in this study both survived less than
2 years since the diagnosis. The other one than the
case of Bormann type IV gastric cancer was diag-
nosed with relatively small lesion, however revealed
peritoneal seeding and was unable to undergo cura-
tive treatment. These cases show that regular biennial
endoscopy cannot be the perfect screening for gastric
cancer in a high prevalence area and customised
screening or effective way of prevention is needed for
high risk individuals.
In multivariable analysis, age < 60, H. pylori infec-
tion and absent/mild atrophic gastritis were demon-
strated to be independent risk factors for EUT-IGN.
Also, young age, female gender, and absent/mild atro-
phic gastritis were shown to be related with EUT-IGC
in subgroup analysis among IGCs. Such factors are all
known risk factors for the diffuse type gastric cancers
[29, 30]. This means that endoscopic screening with
two-year interval may not be enough for rapidly
growing types of gastric cancers including those with
undifferentiated histology. In current study, we did
not count undifferentiated gastric cancers as the ex-
panded criteria for ESD. Some researchers consider
undifferentiated gastric cancers < 2 cm as a possible
candidate for ESD [22, 23], however there are still
controversy on this issue due to the possibility of
lymph node metastasis [34, 35]. In this study, undif-
ferentiated cancers were all included in the EUT-IGN
group regardless of size. Two-thirds of undifferenti-
ated cancers were larger than 2 cm, showing the rapid
progression of undifferentiated cancers. Recent studies
have reported that the long-term outcome of ESD
was not different from that of surgery among undif-
ferentiated gastric cancers < 2 cm [36, 37]. Taking this
into account, under the assumption that undifferenti-
ated cancers < 2 cm can be established as candidate
for ESD, more intensive screening endoscopy less
than two-year interval would be helpful for a high-
risk group of undifferentiated gastric cancer. There
have been several studies suggesting endoscopic
screening with less than 2 years of interval [13–15].
We suppose our current result is in line with these
studies in that it showed insufficiency of uniform
biennial screening for early detection of gastric
neoplasms.
Another solution for prevention of IGN, which is more
likely to be acceptable in clinical practice would be ex-
tensive H. pylori eradication in adults, especially those
younger than 60 years old. In our results, EUT-GN
showed a tendency of lower disease-specific survival and
included AGC cases. In general, gastric cancers in young
ages are more likely to be aggressive and diagnosed at
advanced stages. Therefore, H. pylori eradication for
young adults regardless of the existence or severity of
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gastric atrophy might be helpful to reduce mortality
from gastric cancer in a certain sub-population.
In this study, the median interval since last endoscopy
was 12 months. This means that most of the enrolled
subjects underwent endoscopy annually, showing that
interval cancer can occur despite annual endoscopy.
This is the reason why we designed this study. Some
people develop gastric cancer very rapidly and even
some skip the premalignant steps such as atrophy/intes-
tinal metaplasia or dysplasia. Therefore, we performed
subgroup analysis among only cancers excluding dyspla-
sia, and where we found that IGC shows similar charac-
teristics with IGN.
There are several limitations in this study. First, we
did not compare the characteristics of EUT-IGN with
healthy control, which made it unable to evaluate the
general risk factors for EUT-IGN. However, healthy con-
trol is not considered indispensable since the risk factors
for overall gastric cancer is already well-known. Second,
we did not investigate gastrointestinal symptoms of the
participants. The reason why these participants under-
went screening within 2 years was not achieved. How-
ever, even though the recommended gastric cancer
screening interval is 2 years by the National Cancer
Screening Program in Korea, opportunistic screening is
frequently performed with a shorter interval due to ei-
ther the screenee’s preference or previously defined risk
factors. Third, as our study included subjects over more
than a decade of time, there were technical improvement
in the endoscopic device. However, we could not adjust
this factor.
Conclusions
Considering that one out of six IGNs were EUT-IGNs,
current uniform screening with biennial endoscopy
seems not enough to improve the prognosis of rapid
growing neoplasms such as undifferentiated cancers.
Also such rapid growing neoplasms tended to show rela-
tively low disease specific survival. Therefore more me-
ticulous and high-quality screening endoscopy which
include close observation especially at proximal area
with enough time should be applied for adults, especially
those younger than 60 years old with H. pylori infection
before the development of severe gastric atrophy.
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